Additionally, they updated the hematological replacement therapy required for surgery utilizing continuous infusion versus bolus injection of standard and extended half-life Factor VIII (FVIII) concentrates in individuals with severe hemophilia A. They mentioned two important complications of surgery: venous thromboembolism (VTE) and the impact of inhibitors. Here, F8 is linked to hemophilia A.